143 related articles for article (PubMed ID: 10504332)
1. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms.
Mikhailenko I; Considine W; Argraves KM; Loukinov D; Hyman BT; Strickland DK
J Cell Sci; 1999 Oct; 112 ( Pt 19)():3269-81. PubMed ID: 10504332
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
Horn IR; van den Berg BM; van der Meijden PZ; Pannekoek H; van Zonneveld AJ
J Biol Chem; 1997 May; 272(21):13608-13. PubMed ID: 9153209
[TBL] [Abstract][Full Text] [Related]
3. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties.
Neels JG; van Den Berg BM; Lookene A; Olivecrona G; Pannekoek H; van Zonneveld AJ
J Biol Chem; 1999 Oct; 274(44):31305-11. PubMed ID: 10531329
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
5. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
[TBL] [Abstract][Full Text] [Related]
7. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
[TBL] [Abstract][Full Text] [Related]
8. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
9. Ligand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein.
Rettenberger PM; Oka K; Ellgaard L; Petersen HH; Christensen A; Martensen PM; Monard D; Etzerodt M; Chan L; Andreasen PA
J Biol Chem; 1999 Mar; 274(13):8973-80. PubMed ID: 10085143
[TBL] [Abstract][Full Text] [Related]
10. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
[TBL] [Abstract][Full Text] [Related]
11. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein.
Willnow TE; Orth K; Herz J
J Biol Chem; 1994 Jun; 269(22):15827-32. PubMed ID: 7515061
[TBL] [Abstract][Full Text] [Related]
12. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes.
Argraves KM; Battey FD; MacCalman CD; McCrae KR; Gåfvels M; Kozarsky KF; Chappell DA; Strauss JF; Strickland DK
J Biol Chem; 1995 Nov; 270(44):26550-7. PubMed ID: 7592875
[TBL] [Abstract][Full Text] [Related]
13. Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site.
Nielsen MS; Nykjaer A; Warshawsky I; Schwartz AL; Gliemann J
J Biol Chem; 1995 Oct; 270(40):23713-9. PubMed ID: 7559542
[TBL] [Abstract][Full Text] [Related]
14. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
[TBL] [Abstract][Full Text] [Related]
15. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
[TBL] [Abstract][Full Text] [Related]
16. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.
Liu CX; Li Y; Obermoeller-McCormick LM; Schwartz AL; Bu G
J Biol Chem; 2001 Aug; 276(31):28889-96. PubMed ID: 11384978
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
18. The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor.
Battey FD; Gåfvels ME; FitzGerald DJ; Argraves WS; Chappell DA; Strauss JF; Strickland DK
J Biol Chem; 1994 Sep; 269(37):23268-73. PubMed ID: 8083232
[TBL] [Abstract][Full Text] [Related]
19. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
[TBL] [Abstract][Full Text] [Related]
20. Intracellular fate of LDL receptor family members depends on the cooperation between their ligand-binding and EGF domains.
Van Hoof D; Rodenburg KW; Van der Horst DJ
J Cell Sci; 2005 Mar; 118(Pt 6):1309-20. PubMed ID: 15741231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
